Nutriband provides product development update for its lead product aversa fentanyl

Orlando, fl / accesswire / june 20, 2024 / nutriband inc.("company") (nasdaq:ntrb)(nasdaq:ntrbw) provides an update on its aversa fentanyl product development program to shareholders as it aims to complete scale-up of the commercial manufacturing process and move towards the single phase 1 human abuse potential study prior to nda filing. as previously reported, the company with its partner kindeva drug delivery completed the feasibility agreement and entered into a commercial development and clinical supply agreement to manufacture product for the human abuse potential clinical study in support of a new drug application (nda) to be submitted to fda.
NTRB Ratings Summary
NTRB Quant Ranking